Fluvoxamine Shows Promise in Reducing Long COVID Fatigue

A low-cost antidepressant, fluvoxamine, is demonstrating significant potential in alleviating persistent fatigue associated with long COVID, according to recent clinical trial results. The findings offer a glimmer of hope for the millions worldwide grappling with the debilitating symptom.

What is Long COVID Fatigue?

Long COVID refers to a range of symptoms that persist for weeks or months after the initial COVID-19 infection has resolved. Fatigue is one of the most commonly reported and disabling symptoms, often described as overwhelming exhaustion that interferes with daily activities. Many individuals with long COVID experience fatigue severe enough to impact their ability to work or care for their families.

The REVIVE-TOGETHER Trial: Fluvoxamine’s Impact

A randomized, placebo-controlled clinical trial involving 399 participants with significant fatigue – rated at least four points on a seven-point Fatigue Severity Scale – revealed promising results for fluvoxamine. Participants receiving fluvoxamine were nearly 50% more likely to report a reduction in fatigue severity (rated three or less on the scale) after 30 days compared to those receiving a placebo. After 60 days, fluvoxamine lowered self-reported fatigue ratings by approximately half a point. CIDRAP

Importantly, those taking fluvoxamine also reported improved quality of life and experienced fewer adverse events than the placebo group. Medical Xpress, News Medical

Metformin: A Disappointing Result

The trial also investigated the potential of metformin, a medication commonly used to treat diabetes, to alleviate long COVID fatigue. However, the study found that metformin did not demonstrate a significant benefit over a placebo. CIDRAP, MedPage Today

Why Fluvoxamine May Work

While the exact mechanism is still under investigation, fluvoxamine is believed to modulate the immune system and reduce inflammation, potentially addressing some of the underlying biological processes contributing to long COVID fatigue. News Medical

Expert Perspective

Jamie Forrest, PhD, MPH, scientific director of the University of British Columbia’s Health Equity & Resilience Observatory, expressed optimism about the findings, stating that fluvoxamine “is worth trying in people with long COVID.” CIDRAP His goal, he says, is to “secure people back to feeling normal.”

Key Takeaways

• Fluvoxamine, a widely available antidepressant, significantly reduced fatigue and improved quality of life in adults with long COVID in a recent clinical trial.
• Participants taking fluvoxamine were nearly 50% more likely to report reduced fatigue after 30 days.
• Metformin did not demonstrate a significant benefit in alleviating long COVID fatigue.
• Fluvoxamine appears to be a safe and well-tolerated treatment option.

Looking Ahead

These findings represent a promising step forward in the search for effective treatments for long COVID. Further research is needed to confirm these results and to better understand the optimal duration of treatment and the specific patient populations who may benefit most from fluvoxamine.